Daniel Petrylak, MD
Co-director, Signal Transduction Research Program
Yale University Smilow Cancer Center
New Haven, Connecticut
Dr. Daniel Petrylak received his medical degree from Case Western Reserve University School of Medicine, Cleveland, Ohio. He completed his internal medicine residency at Albert Einstein College of Medicine/Jacobi Medical Center, and his fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Petrylak is currently director of genitourinary oncology, and co-director of the Signal Transduction Program at Yale University Cancer Center.
A recognized international leader in the field, Dr. Petrylak has served on the program committee for the annual meetings of the American Urological Association, as well as for the American Society of Clinical Oncology. He also has served as a committee member for the Devices and Immunolgicals section of the Food and Drug Administration. In addition, he is the head of the advanced bladder subcommittee in the Southwest Oncology Group Genitourinary Committee. Dr. Petrylak, who is involved in clinical trials research on a local, national, and international level, served as principal investigator or co-investigator on seven Southwest Oncology Group Protocols. He also helped to design and served as principal investigator for the SPARC trial, an international registration trial evaluating the activity of satraplatin as a second-line therapy for hormone refractory prostate cancer. He has published extensively in The New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, as well as Cancer Research, and Clinical Cancer Research.